London, UK – 28 August 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary lateral CAR platform, today announced that it will attend the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. Filippo Petti, Chief Executive […]
Resolution leadership team joined by world leading clinical hepatologist Elliot Tapper, MD, FAASLD, and EMERALD Chief Investigator Professor Jonathan Fallowfield Edinburgh and London, UK, 27 August 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces that it will host a virtual […]
New York, July 30, 2025 – KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company. This strategic partnership will enable KKR to enhance its capabilities in biopharma royalty and credit investing, while expanding the […]
Financing to support Phase 2 trials of lead program for schizophrenia and Alzheimer’s disease psychosis, and expansion of CNS pipeline San Francisco, US, 28 July 2025 – Novo Holdings, a leading life science investor, today announced its participation in a $372.5 million Series D financing of MapLight Therapeutics (“MapLight”), a clinical-stage biopharmaceutical company focused on improving […]
Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a […]
